Loading clinical trials...
Loading clinical trials...
Neoadjuvant Chemotherapy and PD-1 Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Conditions
Interventions
Toripalimab + Chemotherapy
Toripalimab
+1 more
Locations
1
United States
Johns Hopkins Hospital East Baltimore
Baltimore, Maryland, United States
Start Date
February 18, 2026
Primary Completion Date
October 1, 2030
Completion Date
December 1, 2030
Last Updated
April 23, 2026
NCT06563479
NCT06532279
NCT05969860
NCT06731933
NCT06477692
NCT02128906
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions